![Neoadjuvant treatment of HER 2-positive breast cancer – pathological complete response ( pCR ) as a surrogate of long term outcomes in the context of regulatory guidelines and reimbursement recommendations | Semantic Scholar Neoadjuvant treatment of HER 2-positive breast cancer – pathological complete response ( pCR ) as a surrogate of long term outcomes in the context of regulatory guidelines and reimbursement recommendations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2da9c7d2a6f39a0fe209056652e3f8b8a0df708e/4-Table1-1.png)
Neoadjuvant treatment of HER 2-positive breast cancer – pathological complete response ( pCR ) as a surrogate of long term outcomes in the context of regulatory guidelines and reimbursement recommendations | Semantic Scholar
Auditory and sexual preferences for a father's song can co-emerge in female Bengalese finches | PLOS ONE
![A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer | Scientific Reports A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-91049-x/MediaObjects/41598_2021_91049_Fig1_HTML.png)
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer | Scientific Reports
![Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) | SpringerLink Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-022-00874-1/MediaObjects/11523_2022_874_Fig3_HTML.png)